Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions

Journal of Clinical Oncology

Volumn 20, Issue 2, 2002, Pages 574-581

  Gelderblom, Hans ^a   Mross, Klaus ^a   Ten Tije, Albert J ^a   Behringer, Dirk ^a   Mielke, Stephan ^a   Van Zomeren, Desirée M ^a   Verweij, Jaap ^a   Sparreboom, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; DRUG BINDING; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; HUMAN; MALE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCEROL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PACLITAXEL; SURFACE-ACTIVE AGENTS; THROMBOCYTOPENIA; TIME FACTORS;

EID: 0037080432     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.2.574     Document Type: Article

References (38)

1. Free drug monitoring
2. Problems in therapeutic drug monitoring: Free drug level monitoring
3. Prospective evaluation of a model for predicting etoposide protein binding in cancer patients
4. Variability in teniposide plasma protein binding is correlated with serum albumin concentrations
5. Relation between systemic exposure to unbound etoposide and hematological toxicity
6. Relation between unbound plasma concentrations and toxicity in a prolonged etoposide schedule
7. Measurement of fraction unbound paclitaxel in human plasma
8. Cremophor EL-mediated alteration of paclitaxel distribution in blood: Clinical pharmacokinetic implications
9. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
10. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
11. Interrelationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients
12. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles
13. The pharmacokinetics of a 1-h paclitaxel infusion
14. Quantitation of Cremophor EL in human plasma samples using a colorimetric dyebinding microassay
15. Linearized colorimetric assay for Cremophor EL: Application to pharmacokinetics after 1-hour paclitaxel infusions
16. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
17. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo
18. Pharmacokinetics (PK) of, and limited sampling strategies (LSS) for 1-hour paclitaxel infusions
19. Phase I trial of weekly paclitaxel in advanced lung cancer
20. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer
21. Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration
22. Paclitaxel via 1-hour infusion: Rationale and pharmacology
23. Phase I trial of Taxol given as a 3-hour infusion every 21 days
24. A phase I trial of Taxol given by a 6-hour intravenous infusion
25. Phase I trial of Taxol given as a 24-h infusion every 21 days: Responses observed in metastatic melanoma
26. Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion
27. Paclitaxel in doxorubicinrefractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion
28. Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: A phase I study
29. Rapid esterasesensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice
30. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: An in vitro study
31. Formation of complementactivating particles in aqueous solution of taxol: Possible role in hypersensitivity reactions
32. Role of formulation vehicles in taxane pharmacology
33. The downsides and potential of vehicle selection for drug formulation
34. Potential neurotoxicity of the solvent vehicle for cyclosporine
35. Neurotoxicity of taxol
36. Neurotoxicity of paclitaxel infused weekly over one versus three hours: Preliminary results of a phase III trial
37. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
38. Mechanismbased pharmacokinetic model for paclitaxel